Macrophages/Microglia Represent the Major Source of Indolamine 2,3-Dioxygenase Expression in Melanoma Metastases of the Brain.
Aged
Brain
/ immunology
Brain Neoplasms
/ immunology
CD8-Positive T-Lymphocytes
/ immunology
Cohort Studies
Female
Humans
Immunotherapy
Indoleamine-Pyrrole 2,3,-Dioxygenase
/ metabolism
Kaplan-Meier Estimate
Lymphocytes, Tumor-Infiltrating
/ immunology
Macrophages
/ metabolism
Male
Melanoma
/ immunology
Microglia
/ metabolism
Middle Aged
Prognosis
Survival Analysis
Tumor Microenvironment
/ immunology
IDO
brain metastases
immune checkpoint molecules
immunogenic microenvironment
melanoma
tumor-associated macrophages
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2020
2020
Historique:
received:
03
09
2019
accepted:
16
01
2020
entrez:
3
3
2020
pubmed:
3
3
2020
medline:
9
3
2021
Statut:
epublish
Résumé
The manifestation of brain metastases in patients with advanced melanoma is a common event that limits patient's survival and quality of life. The immunosuppressive properties of the brain parenchyma are very different compared to the rest of the body, making it plausible that the current success of cancer immunotherapies is specifically limited here. In melanoma brain metastases, the reciprocal interplay between immunosuppressive mediators such as indoleamine 2, 3-dioxygenase (IDO) or programmed cell death-ligand 1 (PD-L1) in the context of neoplastic transformation are far from being understood. Therefore, we analyzed the immunoreactive infiltrate (CD45, CD3, CD8, Forkhead box P3 [FoxP3], CD11c, CD23, CD123, CD68, Allograft Inflammatory factor 1[AIF-1]) and PD-L1 with respect to IDO expression and localization in melanoma brain metastases but also in matched metastases at extracranial sites to correlate intra- and interpatient data with therapy response and survival. Comparative tissue analysis identified macrophages/microglia as the major source of IDO expression in melanoma brain metastases. In contrast to the tumor infiltrating lymphocytes, melanoma cells
Identifiants
pubmed: 32117271
doi: 10.3389/fimmu.2020.00120
pmc: PMC7013086
doi:
Substances chimiques
Indoleamine-Pyrrole 2,3,-Dioxygenase
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
120Informations de copyright
Copyright © 2020 Herrera-Rios, Mughal, Teuber-Hanselmann, Pierscianek, Sucker, Jansen, Schimming, Klode, Reifenberger, Felsberg, Keyvani, Brors, Sure, Reifenberger, Schadendorf and Helfrich.
Références
Trends Immunol. 2016 Mar;37(3):181-192
pubmed: 26877243
Mol Immunol. 2011 Oct;49(1-2):253-9
pubmed: 21937116
Cancer Metastasis Rev. 2012 Dec;31(3-4):429-40
pubmed: 22699312
Am Soc Clin Oncol Educ Book. 2013;:399-403
pubmed: 23714560
Eur J Cancer. 2017 May;76:167-182
pubmed: 28324751
J Immunother Cancer. 2019 Mar 20;7(1):80
pubmed: 30894212
Cancer Res. 2018 Feb 1;78(3):610-616
pubmed: 29212855
EMBO J. 1991 Nov;10(11):3167-75
pubmed: 1915289
Neuro Oncol. 2017 Oct 19;19(11):1511-1521
pubmed: 28444227
Immunotherapy. 2019 Jun;11(8):677-689
pubmed: 31088236
Trends Immunol. 2006 Feb;27(2):68-73
pubmed: 16406698
Front Immunol. 2019 Jul 24;10:1713
pubmed: 31396225
Eur J Cancer. 2017 Apr;75:47-55
pubmed: 28214657
Curr Oncol Rep. 2013 Oct;15(5):483-91
pubmed: 23954973
Immunol Invest. 2012;41(6-7):765-97
pubmed: 23017145
Int J Mol Sci. 2017 Dec 28;19(1):
pubmed: 29283429
Clin Exp Immunol. 1998 Nov;114(2):196-203
pubmed: 9822276
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
FASEB J. 1991 Aug;5(11):2516-22
pubmed: 1907934
Neoplasia. 2018 Feb;20(2):218-225
pubmed: 29331888
Neuro Oncol. 2017 Feb 1;19(2):162-174
pubmed: 28391295
Nat Clin Pract Oncol. 2008 Sep;5(9):557-61
pubmed: 18665147
Science. 2002 Sep 13;297(5588):1867-70
pubmed: 12228717
J Immunol. 2009 Aug 15;183(4):2475-83
pubmed: 19635913
Nat Rev Immunol. 2006 Nov;6(11):836-48
pubmed: 17063185
Am J Surg. 1978 Jun;135(6):807-10
pubmed: 665907
J Clin Oncol. 2016 Dec;34(34):4102-4109
pubmed: 27863197
Chin Clin Oncol. 2015 Jun;4(2):21
pubmed: 26112807
Cancer Res. 2002 May 1;62(9):2592-9
pubmed: 11980654
Eur J Cancer. 2012 Sep;48(13):2004-11
pubmed: 22033321
J Clin Oncol. 2012 May 1;30(13):1406-7
pubmed: 22412128
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Cancer Cell. 2017 Mar 13;31(3):326-341
pubmed: 28292436
Clin Cancer Res. 2006 Feb 15;12(4):1144-51
pubmed: 16489067
Lancet Oncol. 2012 May;13(5):459-65
pubmed: 22456429
Lancet. 2012 May 19;379(9829):1893-901
pubmed: 22608338
Oncotarget. 2018 May 18;9(38):25216-25224
pubmed: 29861865
Oncotarget. 2015 Dec 1;6(38):40836-49
pubmed: 26517811
Cancer. 2011 Apr 15;117(8):1687-96
pubmed: 20960525
Lancet Oncol. 2019 Aug;20(8):1083-1097
pubmed: 31221619
Sci Rep. 2014 Mar 21;4:4422
pubmed: 24651727
Clin Cancer Res. 2019 Jun 1;25(11):3220-3228
pubmed: 30770348
Clin Cancer Res. 2013 Apr 15;19(8):2232-9
pubmed: 23444228
J Exp Med. 2011 Aug 1;208(8):1695-705
pubmed: 21788405
Clin Cancer Res. 2017 Aug 15;23(16):4671-4679
pubmed: 28592629
Clin Neurol Neurosurg. 2013 Sep;115(9):1721-8
pubmed: 23643143
J Exp Med. 2010 Mar 15;207(3):491-503
pubmed: 20194633
Oncoimmunology. 2015 Jun 9;5(1):e1057388
pubmed: 26942067
Vaccines (Basel). 2015 Sep 10;3(3):703-29
pubmed: 26378585
Lancet Oncol. 2010 Feb;11(2):155-64
pubmed: 20004617
Nature. 2015 Jul 16;523(7560):337-41
pubmed: 26030524
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
CA Cancer J Clin. 2017 Nov;67(6):472-492
pubmed: 29028110
Cancer Res. 2019 Feb 1;79(3):423-436
pubmed: 30679177
Lancet Oncol. 2012 Nov;13(11):1087-95
pubmed: 23051966
Br J Dermatol. 2014 Nov;171(5):987-95
pubmed: 24814041
Clin Exp Metastasis. 2013 Jan;30(1):69-81
pubmed: 22752508
Cancer Immunol Immunother. 2018 Aug;67(8):1305-1315
pubmed: 29959458
Histopathology. 2015 Jan;66(2):289-99
pubmed: 25314639
Eur Radiol. 2013 Sep;23(9):2622-7
pubmed: 23670820
J Transl Med. 2018 Aug 6;16(1):219
pubmed: 30081936
J Neurooncol. 2016 Jan;126(2):355-60
pubmed: 26511495
Am Soc Clin Oncol Educ Book. 2018 May 23;38:741-750
pubmed: 30231345
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
Sci Transl Med. 2013 Aug 28;5(200):200ra116
pubmed: 23986400
Science. 2011 Mar 25;331(6024):1559-64
pubmed: 21436443
Lancet Oncol. 2018 May;19(5):672-681
pubmed: 29602646
Lancet Oncol. 2016 Jul;17(7):976-983
pubmed: 27267608
J Exp Clin Cancer Res. 2011 Jan 18;30:10
pubmed: 21244695
J Immunother Cancer. 2014 Feb 18;2:3
pubmed: 24829760
N Engl J Med. 2012 Jun 28;366(26):2517-9
pubmed: 22658126
J Exp Med. 2015 Jun 29;212(7):991-9
pubmed: 26077718
Clin Cancer Res. 2008 Apr 15;14(8):2310-7
pubmed: 18413819